Key Points
- Illumina SVP Christensen Jakob Wedel sold 700 shares on May 6 at an average price of $139.04 for about $97,328, reducing his stake by 4.44% to 15,056 shares valued at roughly $2.09 million; the sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Company results beat expectations: Illumina reported Q1 EPS of $1.15 (vs. $1.05 expected) and revenue of $1.09B (vs. $1.07B), set FY2026 guidance of $5.150–$5.300 EPS, and currently carries an average analyst rating of "Hold" with a mean target of $131.06.
Illumina, Inc. (NASDAQ:ILMN - Get Free Report) SVP Christensen Jakob Wedel sold 700 shares of the business's stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the completion of the transaction, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This represents a 4.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Illumina Stock Down 2.7%
Shares of Illumina stock opened at $138.71 on Friday. The stock's 50-day moving average is $126.86 and its 200 day moving average is $127.86. Illumina, Inc. has a one year low of $75.24 and a one year high of $155.53. The firm has a market cap of $20.99 billion, a price-to-earnings ratio of 25.22, a PEG ratio of 2.36 and a beta of 1.42. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36.
Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm's revenue for the quarter was up 4.8% on a year-over-year basis. During the same period in the previous year, the company posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts anticipate that Illumina, Inc. will post 5.2 EPS for the current year.
Institutional Investors Weigh In On Illumina
Institutional investors and hedge funds have recently made changes to their positions in the business. Capital World Investors boosted its stake in Illumina by 0.6% during the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company's stock valued at $2,636,483,000 after purchasing an additional 124,323 shares during the last quarter. State Street Corp raised its stake in shares of Illumina by 3.2% in the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company's stock worth $811,895,000 after purchasing an additional 190,324 shares during the last quarter. WCM Investment Management LLC lifted its holdings in shares of Illumina by 45.5% in the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company's stock valued at $715,579,000 after purchasing an additional 1,851,848 shares in the last quarter. AQR Capital Management LLC boosted its position in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company's stock valued at $580,531,000 after buying an additional 1,028,099 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Illumina by 4.8% during the fourth quarter. Geode Capital Management LLC now owns 2,869,047 shares of the life sciences company's stock valued at $375,260,000 after buying an additional 130,139 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.
Analysts Set New Price Targets
Several brokerages recently issued reports on ILMN. Canaccord Genuity Group cut their target price on shares of Illumina from $150.00 to $140.00 and set a "hold" rating on the stock in a research note on Friday, May 1st. Evercore reaffirmed an "outperform" rating on shares of Illumina in a research note on Friday, May 1st. Barclays upped their price objective on shares of Illumina from $110.00 to $122.00 and gave the company an "underweight" rating in a report on Friday, May 1st. Wall Street Zen raised shares of Illumina from a "buy" rating to a "strong-buy" rating in a research report on Saturday, February 14th. Finally, JPMorgan Chase & Co. raised their target price on Illumina from $120.00 to $125.00 and gave the company a "neutral" rating in a research note on Friday, May 1st. Six equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Hold" and an average target price of $131.06.
View Our Latest Report on ILMN
Illumina Company Profile
(
Get Free Report)
Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.
The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
